Ney Carter Borges: Non-HDL Cholesterol vs ApoB Both Matter for ASCVD Risk
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn about a recent article by Camilla Ditlev Lindhart Johannesen et al. published in JAMA Cardiology, adding:
“Non-HDL Cholesterol vs ApoB: Both Matter for ASCVD Risk
A contemporary cohort analysis from the Copenhagen General Population Study evaluated 94,398 statin-naïve individuals over a median follow-up of 13.2 years to determine whether non-HDL cholesterol or apolipoprotein B (apoB) provides superior prediction of atherosclerotic cardiovascular disease (ASCVD).
The investigators demonstrated that both biomarkers independently predicted myocardial infarction (MI) and ASCVD events. For each 1-standard deviation increase, non-HDL cholesterol was associated with a 16% higher ASCVD risk (HR 1.16; 95% CI 1.13–1.19), while apoB showed a comparable 14% increase (HR 1.14; 95% CI 1.12–1.17).
A particularly important finding emerged from discordance analyses. Individuals with elevated apoB despite lower non-HDL cholesterol still exhibited significantly higher cardiovascular risk, and the reverse pattern was equally true.
Patients with concordantly elevated non-HDL cholesterol and apoB had the greatest risk burden, with MI risk increasing by 69% (HR 1.69; 95% CI 1.53–1.85).
These findings reinforce the biological concept that both cholesterol content and lipoprotein particle number contribute to atherogenesis. ApoB reflects the number of circulating atherogenic particles, whereas non-HDL cholesterol better captures total cholesterol carried within these particles.
The study suggests that relying on only one marker may overlook clinically relevant residual risk.
From a practical cardiometabolic perspective, the data support combined assessment of non-HDL cholesterol and apoB, particularly in patients with metabolic syndrome, diabetes, hypertriglyceridemia, obesity, or discordant lipid profiles.
The authors conclude that there is no ‘one-marker-fits-all’ solution for ASCVD risk stratification and that integrated lipid assessment may improve future preventive strategies and guideline refinement.”
Title: Non-HDL Cholesterol and Apolipoprotein B Measures and Risk of Atherosclerotic Cardiovascular Disease
Authors: Camilla Ditlev Lindhart Johannesen, Anne Langsted, Borge Gronne Nordestgaard, Martin Bodtker Mortensen
Find more posts featuring Ney Carter Borges on Hemostasis Today.
-
Oct 20, 2026, 16:51Suzan Nakasendwa: A Growing Stroke Challenge in Uganda
-
Oct 20, 2026, 16:38Steve Moon: How Does Smoking Cessation Duration Affect Ischemic Stroke Risk
-
Oct 20, 2026, 16:25Cedrice Mentor: Reducing Platelet Wastage Through Cold Storage
-
Oct 20, 2026, 16:09Thirunavukkarasu Angappan: Can a Purified Fibrinogen Concentrate Replace Cryoprecipitate
-
Oct 20, 2026, 16:01Kalyan Roy: Platelet Conservation Through Evidence-Based Transfusion Practice
-
Oct 20, 2026, 15:28Stacy E. Croteau: 33 Countries, One Mission – Better Bleeding Disorder Care
-
Oct 20, 2026, 15:19Teresa Barnes: What Does a Pulmonary Embolism Mean for Jalen Hurts?
-
Oct 20, 2026, 15:04Laura S.: Could Speaking Up Prevent Maternal Deaths from Thrombosis?
-
Oct 20, 2026, 14:44Pete Stibbs: VTE in Professional Athletes – When Fitness Is Not Enough